GlassScriptPhysician profile
Megan E Rathel
NPI 1588016646
$907.49
in general payments reported to CMS, 2019-2025
21 companies · $150 in 2025
The $150 reported for 2025 was less than what a typical Family provider received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $267 · 2022: $110 · 2023: $197 · 2024: $184 · 2025: $150.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $531.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $530.71 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Glaxosmithkline, LLC. | $128.30 | 2022-2024 | Trelegy Ellipta, Arexvy, Shingrix |
| Sumitomo Pharma America, INC. | $117.12 | 2023-2025 | Gemtesa |
| Pfizer INC. | $109.24 | 2021 | |
| Novo Nordisk INC | $88.22 | 2023-2024 | Rybelsus, Ozempic, Wegovy |
| Sunovion Pharmaceuticals INC. | $69.30 | 2021-2022 | |
| Xeris Pharmaceuticals, INC. | $54.32 | 2023-2025 | Gvoke Hypopen |
| Boehringer Ingelheim Pharmaceuticals, INC. | $43.23 | 2021-2023 | Jardiance |
| Astrazeneca Pharmaceuticals LP | $40.48 | 2023-2024 | Farxiga |
| Bayer Healthcare Pharmaceuticals INC. | $38.26 | 2022-2023 | |
| Cvrx, INC. | $36.10 | 2025 | Barostim Neo System |
| Amgen INC. | $30.91 | 2021-2023 | Repatha, Otezla |
| Boston Scientific Corporation | $20.91 | 2022 | |
| Abbvie INC. | $18.88 | 2024 | |
| Astellas Pharma US INC | $18.76 | 2021 | |
| Exact Sciences Corporation | $17.58 | 2024 | Cologuard Collection Kit |
Show all 21 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $15.77 | 2025 | Caplyta |
| Kowa Pharmaceuticals America, INC. | $14.35 | 2021 | |
| Janssen Pharmaceuticals, INC | $11.85 | 2022 | |
| Lilly USA, LLC | $11.65 | 2021 | |
| Sanofi-Aventis U.S. LLC | $11.19 | 2021 | |
| Supernus Pharmaceuticals, INC. | $11.07 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Megan Rathel listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.